Walleye Trading’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-6,602
| Closed | -$266K | – | 3957 |
|
|
2026
Q1 | $266K | Sell |
6,602
-6,097
| -48% | -$131K | ﹤0.01% | 2949 |
|
|
2025
Q4 | $319K | Buy |
12,699
+2,258
| +22% | +$53K | ﹤0.01% | 3115 |
|
|
2025
Q3 | $236K | Buy |
10,441
+9,680
| +1,272% | +$226K | ﹤0.01% | 3252 |
|
|
2025
Q2 | $13.2K | Buy |
+761
| New | +$14.1K | ﹤0.01% | 4014 |
|
|
2024
Q1 | – | Sell |
-12,831
| Closed | -$818K | – | 4717 |
|
|
2023
Q4 | $768K | Sell |
12,831
-12,649
| -50% | -$642K | ﹤0.01% | 2711 |
|
|
2023
Q3 | $969K | Buy |
25,480
+18,484
| +264% | +$812K | ﹤0.01% | 2391 |
|
|
2023
Q2 | $637K | Sell |
6,996
-3,728
| -35% | -$322K | ﹤0.01% | 2553 |
|
|
2023
Q1 | $707K | Buy |
+10,724
| New | +$619K | ﹤0.01% | 2514 |
|
|
2022
Q2 | – | Sell |
-518
| Closed | -$23.6K | – | 5084 |
|
|
2022
Q1 | $26K | Buy |
+518
| New | +$22.9K | ﹤0.01% | 4700 |
|
|
2021
Q3 | – | Sell |
-10,396
| Closed | -$584K | – | 5174 |
|
|
2021
Q2 | $657K | Buy |
+10,396
| New | +$536K | ﹤0.01% | 2597 |
|
|
2020
Q3 | – | Sell |
-5,025
| Closed | -$164K | – | 4062 |
|
|
2020
Q2 | $164K | Buy |
5,025
+4,017
| +399% | +$129K | ﹤0.01% | 3213 |
|
|
2020
Q1 | $27K | Buy |
+1,008
| New | +$35.8K | ﹤0.01% | 3564 |
|
Other funds holding APLS
Walleye Trading's APLS Position: Q2 2026 in Review
Walleye Trading sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 6,602 shares — an estimated $266K sold.
Walleye Trading first reported a position in APLS in Q1 2020 and held it in 12 quarters. The position peaked at $969K in Q3 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Walleye Trading reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Walleye Trading sold 6,602 Apellis Pharmaceuticals shares in Q2 2026, an estimated $266K.
- Walleye Trading first reported a position in Apellis Pharmaceuticals in Q1 2020 and held it in 12 quarters.
- Walleye Trading's Apellis Pharmaceuticals position peaked at $969K in Q3 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Walleye Trading's 13F filing for Q2 2026, filed 3 Aug 2026.